Cholera Vaccines Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The Cholera Vaccines Market has been Segmented by Vaccine Type (Killed Oral O1 with Whole-cell with B-subunit, Killed Oral O1, and O139), Product Type, and Geography

Market Snapshot

cholera vaccines market
Study Period: 2018 - 2026
Base Year: 2020
Fastest Growing Market: North America
Largest Market: Asia Pacific
CAGR: 9.8 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The growth of the global cholera vaccines market can be attributed to multiple factors, such as the increasing incidences of cholera, rising initiatives by public and private entities, and growing awareness regarding cholera across the world. In 2017, 10 million doses of oral cholera vaccines were funded in affected countries via stockpile. This stockpile has been accessed 52 times since the funding, by 18 countries across the world, including Sierra Leone and Haiti. However, a lack of access to adequate care for cholera, coupled with a large number of unreported cases, are expected to pull back the growth of the market.

Scope of the Report

Cholera is caused by Vibrio cholerae via the consumption of contaminated food or water. The infected individuals suffer from severe watery diarrhea, eventually leading to dehydration, which if unattended, may lead to death, owing to access water loss. Oral vaccination has been observed to be the best preventive treatment for cholera and has proved to be very useful to prevent huge outbreaks. There are two basic types of vaccines given for cholera: whole-cell V. cholerae O1, in combination with a recombinant B-subunit of cholera toxin (WC/rBS), and killed oral O1 and O139. Cholera Vaccines Market is segmented By Vaccine Type, By Product Type and Geography.

Vaccine Type
Whole cell V. cholerae O1 with Recombinant B-subunit
Killed Oral O1 and O139
Product
Vaxchora
Dukoral
Shanchol
Other Products
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Whole-cell V. cholerae O1 with a Recombinant B-subunit Segment Captures the Largest Market Share

This oral cholera vaccine containing a combination of recombinant B-subunit and killed whole cell V. cholerae O1 has been marketed since early 1990. This vaccine is observed to provide 80-90% protection for six months, post immunization, and in all the cases of immunization of vaccines aged more than 2 years. In addition to this, this vaccines shows around 50% of protection even after three years of immunization. Hence, the efficacy and long-lasting post immunization protections of the vaccine are expected to propel the segment’s growth over the forecast period.

Cholera Vaccines Market Trend.png

Asia-Pacific is Expected to Grow at a High Rate over the Forecast Period

  • Asia-Pacific captures the largest market share in the global cholera vaccines market, followed by Europe. This can be attributed to the high incidence rate, growing awareness, and availability of efficient preventive solutions. 
  • The APAC market experienced exceptional growth since the launch of the oral cholera vaccine, Shanchol. 
  • According to the statistics of WHO, 12 countries in Asia reported with cholera which constituted about 13% of cases in the total cases worldwide. This statistics showed an overall decrease of 9% from the previous year, owing to growing immunization in the region. 
  • On the other hand, North America is expected to exhibit the fastest growth rate over the forecast period, owing to the launch of the first ever oral cholera vaccine, Vaxchora, in 2016, and the rise in the number of immigrants.
Cholera Vaccines Market - Growth Rate by Region

Competitive Landscape

Some of the significant companies in the market are AstraZeneca, Shantha Biotechnics Private Limited, Valneva SE, Merck & Co. Inc., and PaxVax Inc. The major market players, in order to retain a strong market position, focus on mergers, acquisitions, and product innovation. Also, licensing rights on the vaccines of some major companies give them the leverage of a strong market foothold. For instance, the licensing rights of Dukoral were conferred to Valneva SE, post-acquisition of Crucell Sweden AB, in turn, strengthening the company’s cholera vaccine portfolio and overall market position.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Incidences of Cholera

      2. 4.2.2 Rising Initiatives and Awareness Regarding Immunization

    3. 4.3 Market Restraints

      1. 4.3.1 Lack of Access to Adequate Treatment

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 Vaccine Type

      1. 5.1.1 Whole cell V. cholerae O1 with Recombinant B-subunit

      2. 5.1.2 Killed Oral O1 and O139

    2. 5.2 Product

      1. 5.2.1 Vaxchora

      2. 5.2.2 Dukoral

      3. 5.2.3 Shanchol

      4. 5.2.4 Other Products

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle East & Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle East & Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Astellas Pharma Inc.

      2. 6.1.2 Emergent BioSolutions Inc.

      3. 6.1.3 GlaxoSmithKline plc (GSK)

      4. 6.1.4 Merck & Co. Inc.

      5. 6.1.5 Mitsubishi Tanabe Pharma Corporation

      6. 6.1.6 Sanofi

      7. 6.1.7 Takeda Pharmaceutical Co. Ltd

      8. 6.1.8 Valneva SE

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Development

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Cholera Vaccines Market market is studied from 2018 - 2026.

The Cholera Vaccines Market is growing at a CAGR of 9.8% over the next 5 years.

North America is growing at the highest CAGR over 2021- 2026.

Asia Pacific holds highest share in 2020.

Sanofi, Emergent Biosolutions, Inc., Valneva SE, GlaxoSmithKline LLC, Astellas Pharma Inc. are the major companies operating in Cholera Vaccines Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!